Cite
HARVARD Citation
Wang, M. et al. (n.d.). IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO. Hematological oncology. pp. 142-143. [Online].